Compare · ACHV vs AWH
ACHV vs AWH
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and Aspira Women's Health Inc. (AWH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and AWH operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ACHV carries a market cap of $697.7M.
- ACHV has hit the wire 6 times in the past 4 weeks while AWH has been quiet.
- ACHV has more recent analyst coverage (11 ratings vs 1 for AWH).
- Company
- Achieve Life Sciences Inc.
- Aspira Women's Health Inc.
- Price
- -
- -
- Market cap
- $697.7M
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 6
- 0
- Recent ratings
- 11
- 1
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Aspira Women's Health Inc.
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. It provides OVA1, Overa, and Ova1PLUS to detect the risk of ovarian malignancy. The company also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, it owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, the company is developing diagnostic algorithms; and a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. It has entered into a collaborative research agreement with Baylor Genetics to co-develop a novel ovarian cancer early-detection test; and an agreement with Dana Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer. The company has a strategic alliance with Quest Diagnostics, Incorporated. It serves physician office and hospital laboratories, as well as physicians. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
Latest ACHV
- SEC Form 10-Q filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
- SEC Form 4 filed by Achieve Life Sciences Inc.
- SEC Form 3 filed by Achieve Life Sciences Inc.
Latest AWH
- Aspira Women's Health and Cleveland Clinic Expand Strategic Collaboration to Advance AI-Powered Diagnostics in Women's Health
- Aspira Women's Health (OTCQB:AWHL) Enters Key Growth Phase with Molecular Lab Expansion to Accelerate Breakthrough Endometriosis Blood Test ENDOinform(TM)
- Aspira Announces Third Quarter 2025 Financial Results and Provides Business Update
- Aspira Women's Health Wins Laboratory Service Contract with University of Texas Medical Branch at Galveston
- Aspira Women's Health Announces Equity Capital Infusion of $3.06 Million in Private Placement and Warrant Exercise
- Aspira Women's Health Appoints New Chief Financial Officer
- Aspira Announces Second Quarter 2025 Financial Results and Provides Business Update
- Aspira Women's Health Announces Appointment of Jane Pine Wood to the Board of Directors
- Aspira Women's Health Partners with Dorsata to Offer Access to 300+ Women's Health Practices, 1.5 Million + New Patients
- Aspira Women's Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women's Health